Insilico Medicine Announces Positive Topline Results of ISM001-055 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) Developed Using Generative AI
Highlights: ISM001-055 was safe and well-tolerated with a favorable PK profile in IPF patients Patients who received ISM001-055 showed dose-dependent improvement in the efficacy endpoint, as measured by change in forced vital capacity (FVC) at 12 weeks CAMBRIDGE, Mass., Nov. 12, 2024 /PRNewswire/ -- Insilico Medicine ("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company,...
2022 Tang Prize Masters’ Forum Series Sheds Light on Current Global Challenges
TAIPEI, Oct. 14, 2022 /PRNewswire/ -- Established by Dr. Samuel Yin in 2012, the Tang Prize celebrates its 10th anniversary this year with the 2022 Tang Prize Masters' Forum series that came to a successful conclusion in September. Six 2022 laureates, Professor Jeffrey Sachs for Sustainable Development, Drs. Katalin Kariko, Drew Weissman, Pieter Cullis for Biopharmaceutical Science, Professor Dame...
Chime Biologics Supports Mabgeek to Enter the U.S. Phase III Trials for MG-K10
SHANGHAI, Feb. 21, 2025 /PRNewswire/ -- Chime Biologics, a leading global CDMO that enables its partners' success in biologics, today announced its continued collaboration with Mabgeek in advancing MG-K10, a potential Best-in-Class therapy, a novel IL-4Rα-targeting antibody drug for atopic dermatitis and asthma, into U.S. Phase III trials. Mabgeek had a successful...
Antengene Announces Clearance of U.S. IND for the Phase I Trial of First-in-Class Anti-CD24 Monoclonal Antibody ATG-031
- ATG-031, discovered and developed in-house by Antengene, is the world's first anti-CD24 antibody to advance to the clinic in oncology and Antengene's third drug candidate to enter clinical studies in the U.S. - The Phase I "PERFORM" study will evaluate the safety and tolerability, pharmacology, immunogenicity, and preliminary efficacy of ATG-031...
Bugworks Research Announces the First in Human Phase 1 Study of BWC0977 for the Treatment of Critical Bacterial Infections
BANGALORE, India; SARATOGA, Calif. and ADELAIDE, Australia, Nov. 8, 2021 /PRNewswire/ -- Bugworks research today announced that the first human dose was administered in a Phase 1 clinical trial evaluating BWC0977: a next generation broad-spectrum, novel bacterial topoisomerase inhibitor (NBTI), supported by Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X). Bugworks Announces...
Celebrating Cross-Border Partnerships in Healthcare, Asia Medical Week 2025 Convened Leaders in Bali to Strengthen Excellence and Preparedness
BALI, Indonesia, Sept. 16, 2025 /PRNewswire/ -- The Asia Medical Week (AMW) and the Asia Medical Innovation and Development Forum 2025 officially took place from September 12-13 in Bali with a mission to bring together healthcare leaders from across Asia to strengthen cross-border collaboration and resilience. As a supporting partner, Mindray (300760.SZ), a global leader in medical devices and...
Insilico Medicine Announces the Nomination of Two Preclinical Candidates for PHD2, 12 Months After Program Initiation
NEW YORK and SHANGHAI, Jan. 5, 2022 /PRNewswire/ -- Insilico Medicine, a global clinical-stage biotechnology company specializing in the applications of end-to-end artificial intelligence (AI) for drug discovery and development, today announced that the company has nominated preclinical candidates (PCC) for ISM012-077 and ISM012-042 for the treatment of anemia of chronic kidney disease...
Broncus (02216.HK) announced interim results
The operating revenue had a year-on-year increase by 12.8% in 2022, and the loss narrowed by 62.8%, gradually forming a closed-loop model of "diagnosis + treatment+ chronic disease management" for major pulmonary diseases HANGZHOU, China, Aug. 31, 2022 /PRNewswire/ -- On August 30, 2022, Broncus (02216.HK), the leader in the field of interventional pulmonology in China, reported its interim...
Chang Gung Memorial Hospital Unveils Cellular Therapy: A Beacon of Hope for Cancer Treatment
Cellular Therapy Emerges as a Front-Runner in Medical Innovation TAOYUAN, Oct. 21, 2024 /PRNewswire/ -- Cellular therapy, a revolutionary approach where cells are manipulated outside the body and then reintroduced to treat or prevent diseases, has been recognized in recent years as a highly promising treatment in the medical field. Chang Gung Memorial Hospital in Taiwan has been at...
Jiangsu Recbio Technology Co., Ltd. announced 2023 annual results report and latest progress
TAIZHOU, China, March 21, 2024 /PRNewswire/ -- Innovative vaccine company Recbio (02179.HK) announced its latest progress and annual results for 2023. The company always adhered to the mission of " Protect Human Health With Best-In-Class Vaccines", and achieved the following milestones and progress in research pipeline and business operations. BUSSINESS HIGHLIGHTS REC603-Recombinant HPV 9-valent Vaccine We are...
